Janssen, the pharmaceutical division of Johnson & Johnson LLC, and the Russian biopharmaceutical company Nanolek announce the localization in Russia of the production of Darzalex® (daratumumab) used in the treatment of multiple myeloma.
“The fight against malignant blood diseases is one of Janssen’s main areas of work for many years. Our team is working hard to find new molecules, launch it on the market and expand access to treatment for such serious and difficult to treat diseases like multiple myeloma. This year, our innovative drug daratumumab entered the high-cost nosology program, which gives hope to many patients across the country. In support of this important achievement, we also want to reaffirm our commitment to the local strategy in Russia and are pleased to announce the cooperation with one of the leading Russian manufacturers – the biopharmaceutical company Nanolek – to localize Darzalex®. We believe that this kind of joint work helps to increase the access of Russian patients to innovative therapy,”
commented Katerina Pogodina, Managing Director of Janssen Russia and the CIS, General Director of Johnson & Johnson.
Localization of the drug Darzalex® will be carried out at the facilities of the biomedical complex Nanolek, located in the Kirov region, in accordance with GMP and ISO standards.
Oncology, along with vaccines, is one of the focal points for Nanolek. The company is actively developing a portfolio of drugs for the treatment of cancer, both in partnership with major international companies and through its own developments.